Q910.F Annexin Pharmaceuticals AB (publ)
- Market cap
- EUR 6.82M
- P/E
- -
- P/B
- 32.02x
- ROE
- -1,750.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is Q910.F undervalued?
Graham numberThe Graham number of Annexin Pharmaceuticals AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Annexin Pharmaceuticals AB (publ) fundamental analysis
No fundamental analysis for Annexin Pharmaceuticals AB (publ) yet.
Annexin Pharmaceuticals AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Annexin Pharmaceuticals AB (publ)
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmac…
Full company profileAnnexin Pharmaceuticals AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Annexin Pharmaceuticals AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -52.8M | -40.7M | -44.0M | -50.4M | -36.3M | -44.8M |
| EBITDA | - | -40.7M | -44.0M | -50.2M | -36.9M | -44.8M |
| Net Income | -52.1M | -40.7M | -44.1M | -50.3M | -36.9M | -44.1M |
| EPS | -21 | -14 | -11 | -9.07 | -5.15 | -6.25 |
| Balance Sheet | ||||||
| Total Assets | 52.8M | 36.7M | 26.8M | 19.0M | 30.2M | 7.99M |
| Total Liabilities | 6.06M | 6.53M | 7.95M | 5.32M | 5.22M | 5.47M |
| Shareholders' Equity | 46.7M | 30.2M | 18.8M | 13.7M | 24.9M | 2.52M |
| Cash & Short-term Investments | 49.5M | 31.1M | 21.4M | 16.3M | 27.4M | 5.27M |
| Cash Flow | ||||||
| Operating Cash Flow | -45.0M | -41.2M | -43.4M | -50.2M | -36.9M | -43.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 129K | 0.00 |
| Free Cash Flow | -45.0M | -41.2M | -43.4M | -50.2M | -37.1M | -43.6M |
| Ratios | ||||||
| ROE | -111.6% | -135.1% | -234.2% | -366.5% | -148.0% | -1,750.4% |
| ROA | -98.8% | -111.0% | -164.6% | -264.0% | -122.3% | -552.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Annexin Pharmaceuticals AB (publ) dividends
Annexin Pharmaceuticals AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:100 on May 28, 2025.
Who owns Annexin Pharmaceuticals AB (publ)
- Insiders 54.97%
- Institutions 4.72%
- Public & others 40.31%
- Shares outstanding 8.72M
- Free float 3.88M
Annexin Pharmaceuticals AB (publ) company profile
- Company name
- Annexin Pharmaceuticals AB (publ)
- Ticker
- Q910.F
- ISIN
- SE0025159387
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- Kammakargatan 48, Stockholm, Sweden, 111 60
- Website
- annexinpharma.se
About Annexin Pharmaceuticals AB (publ)
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and repairs cells, as well as counteract unwanted inflammatory and immune cell reactions that is in phase 2 clinical phase for the treatment of ophthalmology, oncology, sickle cell disease, and cardiovascular disease. Annexin Pharmaceuticals AB (publ) was incorporated in 2014 and is based in Stockholm, Sweden.
Annexin Pharmaceuticals AB (publ) management
5- Dr. Anders Haegerstrand M.D., Ph.D.Chief Executive Officer · born 1961
- Ms. Susanne AnderssonChief Financial Officer · born 1971
- Ms. Susan SuchdevChief Operating Officer · born 1972
- Dr. Anna Frostegård M.D., Ph.D.Chief Scientific & Medical Officer · born 1973
- Dr. Mario Fsadni L.L.M., M.Sc.Therapeutic Area Head of Ophthalmology